Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  SanBio Co Ltd    4592   JP3336750009

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

SanBio Co Ltd : half-yearly earnings release

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/07/2017 | 03:15pm CEST
The company will report its earnings for S1 2017 on 09/12/2017. Generally, the company reports earnings better than estimates. In recent months, the 5 analysts from Thomson Reuters consensus have not revised their EPS estimates.

© 4-traders.com 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANBIO CO LTD
09/07SANBIO CO LTD : half-yearly earnings release
07/17 SANBIO : $150 000 shot in the arm for STEM
06/29 SANBIO : South Africa finals of FemBioBiz Acceleration Competition today
04/20 SANBIO : BIH, NEPAD welcome applications for funding
03/14SANBIO CO LTD : annual earnings release
02/27 SANBIO : Study of SanBio's Stem Cell Treatment for Stroke Receives Innovation Aw..
02/24 SANBIO : New FemBioBiz Acceleration Programme to boost women in biosciences
2016SANBIO CO LTD : quaterly earnings release
2016 SANBIO : Receives Patent for its Stem Cell-Based TBI Treatment, Presents Stroke ..
2016 SANBIO : Granted Key Patent in Treatment for Traumatic Brain Injury
More news
News from SeekingAlpha
2016 Picking Winners Still Possible In Q1
Financials ( JPY)
Sales 2018 605 M
EBIT 2018 -
Net income 2018 -3 017 M
Finance 2018 341 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 111x
EV / Sales 2019 23,3x
Capitalization 67 495 M
Chart SANBIO CO LTD
Duration : Period :
SanBio Co Ltd Technical Analysis Chart | 4592 | JP3336750009 | 4-Traders
Technical analysis trends SANBIO CO LTD
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 2 144  JPY
Spread / Average Target 44%
EPS Revisions
Managers
NameTitle
Keita Mori President & Representative Director
Toru Kawanishi Chairman
Damien Bates Chief Medical Officer & Head-Development
Noboru Kotani Independent Director
Yoshihiro Sumiya Manager-Business Administration & IR Contact
Sector and Competitors
1st jan.Capitalization (M$)
SANBIO CO LTD15.37%603
AMGEN28.70%137 303
CELGENE CORPORATION24.61%112 846
GILEAD SCIENCES15.40%107 922
REGENERON PHARMACEUTICALS19.36%46 951
VERTEX PHARMACEUTICALS107.30%38 504